Otezla 10mg, 20mg, 30 mg film-coated tablets, Otezla 10mg, 20mg, 30 mg film-coated tablets clinical trials

A Phase 3B, Multi Center, Open-label Long-term Extension Study of Apremilast (CC-10004) in Pediatric Subjects from 6 Through 17 Years of Age with Moderate to Severe Plaque Psoriasis

This study looks at a medicine called apremilast (Otezla) for young people aged 6 to 17 with moderate to severe psoriasis. It's a long-term study to see how safe and effective the medicine is, and how it affects their growth and development.